Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PTGX 
Protagonist Therapeutics Inc (PTGX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: PTGX (4-star) is a STRONG-BUY. BUY since 73 days. Simulated Profits (51.93%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $90.69
1 Year Target Price $90.69
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 143.6% | Avg. Invested days 63 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.46B USD | Price to earnings Ratio 132.32 | 1Y Target Price 90.69 |
Price to earnings Ratio 132.32 | 1Y Target Price 90.69 | ||
Volume (30-day avg) 10 | Beta 2.2 | 52 Weeks Range 33.70 - 93.25 | Updated Date 12/5/2025 |
52 Weeks Range 33.70 - 93.25 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.94% | Operating Margin (TTM) -985.17% |
Management Effectiveness
Return on Assets (TTM) 1.82% | Return on Equity (TTM) 7.8% |
Valuation
Trailing PE 132.32 | Forward PE 26.39 | Enterprise Value 4815355372 | Price to Sales(TTM) 26.09 |
Enterprise Value 4815355372 | Price to Sales(TTM) 26.09 | ||
Enterprise Value to Revenue 23.02 | Enterprise Value to EBITDA 222 | Shares Outstanding 62515666 | Shares Floating 49893128 |
Shares Outstanding 62515666 | Shares Floating 49893128 | ||
Percent Insiders 1.01 | Percent Institutions 115.74 |
Upturn AI SWOT
Protagonist Therapeutics Inc
Company Overview
History and Background
Protagonist Therapeutics Inc. was founded in 2006. It is a biopharmaceutical company focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs.
Core Business Areas
- Research and Development: Focuses on developing novel peptide therapeutics for diseases with significant unmet needs.
- Drug Discovery Platform: Utilizes a proprietary peptide technology platform to discover and develop innovative therapies.
Leadership and Structure
The leadership team includes Dinesh V. Patel, PhD, President and CEO. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Rusfertide: An injectable hepcidin mimetic being developed for the treatment of polycythemia vera (PV). A Phase 3 trial is underway. Competitors include Jakafi (ruxolitinib) from Incyte.
- PN-943: An oral, gut-restricted alpha-4-beta-7 integrin antagonist for inflammatory bowel disease (IBD). It is in Phase 2 development. Competitors include Entyvio (vedolizumab) from Takeda.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The market for peptide therapeutics is growing due to their potential for improved efficacy and safety profiles.
Positioning
Protagonist Therapeutics is positioned as an innovative company focused on peptide therapeutics. Its competitive advantage lies in its proprietary technology platform.
Total Addressable Market (TAM)
The TAM for polycythemia vera and inflammatory bowel disease is estimated to be in the billions of dollars annually. Protagonist Therapeutics is positioned to capture a portion of this market with its investigational drugs.
Upturn SWOT Analysis
Strengths
- Proprietary peptide technology platform
- Strong intellectual property position
- Experienced management team
- Pipeline of promising drug candidates
Weaknesses
- Reliance on clinical trial success
- High R&D costs
- Dependence on partnerships for development and commercialization
- Limited commercial infrastructure
Opportunities
- Expanding pipeline through internal research and development
- Partnering with larger pharmaceutical companies
- Obtaining regulatory approvals for its drug candidates
- Addressing unmet medical needs in underserved markets
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- INCY
- TAK
Competitive Landscape
Protagonist faces competition from established pharmaceutical companies with larger resources and marketed products. Its advantage lies in its innovative peptide technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by pipeline advancements and partnerships.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include advancing rusfertide and PN-943 through clinical trials.
Summary
Protagonist Therapeutics is a biopharmaceutical company focused on peptide-based therapeutics. Its strength lies in its innovative technology and pipeline, but it faces risks associated with clinical trials and competition. Successful development and commercialization are critical for future growth. The company's long-term potential hinges on positive clinical trial outcomes and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Protagonist Therapeutics Inc. SEC filings
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagonist Therapeutics Inc
Exchange NASDAQ | Headquaters Newark, CA, United States | ||
IPO Launch date 2016-08-11 | CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.protagonist-inc.com |
Full time employees 128 | Website https://www.protagonist-inc.com | ||
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.